Johnson & Johnson's Janssen Pharmaceutical completed its Actelion acquisition for $30 billion in cash. Actelion spun off Idorsia after the acquisition, which has ongoing trials of aprocitentan, or ACT-541468, for chronic insomnia, clazosentan for vasospasm related to aneurysmal subarachnoid hemorrhage and cenerimod for lupus.
Actelion purchased by J&J, spins out Idorsia
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.